Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 929-952

  Samtani, Mahesh N ^a   Raghavan, Nandini ^a   Novak, Gerald ^a   Nandy, Partha ^a   Narayan, Vaibhav A ^a  

^a LLC   (United States)

Author keywords

beta regression; Hippocampal volume; NONMEM ; Trial enrichment

Indexed keywords

ACETYLCHOLINESTERASE; APOLIPOPROTEIN; APOLIPOPROTEIN EPSILON 4; BIOLOGICAL MARKER; MEMANTINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CALCULATION; CEREBROSPINAL FLUID; CLINICAL DEMENTIA RATING SCAL SUM OF BOXES; COGNITION; COMPARATIVE STUDY; DISEASE COURSE; DISEASE SEVERITY; EXPERIMENTAL COGNITIVE TEST; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MEMORY TEST; MILD COGNITIVE IMPAIRMENT; PREDICTIVE VALUE; PSYCHOLOGIC TEST; RATING SCALE; SCORING SYSTEM; SENSITIVITY ANALYSIS; VERY ELDERLY;

EID: 84901431262     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S62323     Document Type: Article

References (43)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356.
2. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289(2): 210-216.
3. Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63(5):674-681.
4. Food and Drug Administration. Draft Guidance for Industry: Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease. Washington, DC: Center for Drug Evaluation and Research; 2013.
5. Food and Drug Administration. Draft Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. Washington, DC: Center for Drug Evaluation and Research; 2013.
6. Cedarbaum JM, Jaros M, Hernandez C, et al; Alzheimer's Disease Neuroimaging Initiative. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. Alzheimers Dement. 2013;9(Suppl 1):S45-S55.
7. Williams MM, Storandt M, Roe CM, Morris JC. Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores. Alzheimers Dement. 2013;9(Suppl 1):S39-S44.
8. European Medicines Agency. Qualification Opinion of a Novel Data Driven Model of Disease Progression and Trial Evaluation in Mild and Moderate Alzheimer's Disease. London: European Medicines Agency; 2013.
9. Romero K, Stephenson D, Rogers J, et al. Advancement of a drug-disease trial model for Alzheimer's disease through a regulatory science path: The CAMD experience. Alzheimers Dement. 2012;8(4):P587-P588.
10. Rogers JA, Polhamus D, Gillespie WR, et al. Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a β regression meta-analysis. J Pharmacokinet Pharmacodyn. 2012;39(5):479-498.
11. European Medicines Agency. Qualification Opinion òf Low Hippocampal Volume (Atrophy) by MRI for Use in Clinical Trials for Regulatory Purpose-in Pre-Dementia Stage Of Alzheimer's Disease. London: European Medicines Agency, 2011. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2011/12/WC500118737.pdf. Accessed April 4, 2014.
12. European Medicines Agency. Qualification Opinion of Alzheimer's Disease Novel Methodologies/Biomarkers for BMS-708163. London: European Medicines Agency, 2011.
13. European Medicines Agency. Qualification Opinion of Alzheimer's Disease Novel Methodologies/Biomarkers for PET Amyloid Imaging (Positive/Negative) as a Biomarker for Enrichment for Use-in Predementia AD Clinical Trials. London: European Medicines Agency, 2011.
14. Jagust WJ, Landau SM, Shaw LM, et al; Alzheimer's Disease Neuroimaging Initiative. Relationships between biomarkers in aging and dementia. Neurology. 2009;73(15):1193-1199.
15. Liu Y, Mattila J, Ruiz MÁ, et al; Alzheimer's Disease Neuroimaging Initiative. Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted Predict AD tool. PLoS One. 2013;8(2):e55246.
16. Alzheimer's Disease Cooperative Study (ADCS). ADNI: Alzheimer's Disease Neuroimaging Initiative. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2013 [updated May 15, 2013]. Available from http://clinicaltrials.gov/ct2/show/NCT00106899. NLM identifier: NCT00106899. Accessed March 26, 2014.
17. ADNI data training part 2. ADNI biostatistics core team. August 1, 2013. Available from http://adni.loni.usc.edu/wp-content/uploads/2012/08/slide_data_training_part2_reduced-size.pdf. Accessed April 4, 2014.
18. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ. NONMEM 7.2.0 Users Guide. Ellicott City, MD: Icon Development Solutions; 1989-2011.
19. Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241-257.
20. Ito K, Corrigan B, Zhao Q, et al; Alzheimer's Disease Neuroimaging Initiative. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Alzheimers Dement. 2011;7(2):151-160.
21. Ito K, Hutmacher MM, Corrigan BW. Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database. J Pharmacokinet Pharmacodyn. 2012;39(6):601-618.
22. William-Faltaos D, Chen Y, Wang Y, Gobburu J, Zhu H. Quantification of disease progression and dropout for Alzheimer's disease. Int J Clin Pharmacol Ther. 2013;51(2):120-131.
23. Tsoularis A, Wallace J. Analysis of logistic growth models. Math Biosci. 2002;179(1):21-55.
24. Samtani MN, Farnum M, Lobanov V, et al; Alzheimer's Disease Neuroimaging Initiative. An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. J Clin Pharmacol. 2012;52(5):629-644.
25. Samtani MN, Raghavan N, Shi Y, et al; Alzheimer's Disease Initiative. Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. Br J Clin Pharmacol. 2013;75(1):146-161.
26. Ashford JW, Schmitt FA. Modeling the time-course of Alzheimer dementia. Curr Psychiatry Rep. 2001;3(1):20-28.
27. Xu XS, Samtani MN, Dunne A, Nandy P, Vermeulen A, De Ridder F; Alzheimer's Disease Neuroimaging Initiative. Mixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundaries. J Pharmacokinet Pharmacodyn. 2013;40(4):537-544.
28. Burnham KP, Anderson DR. Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach. 2nd ed. New York, NY: Springer; 2002.
29. Frederic P, Lad F. Two moments of the logitnormal distribution. Commun Stat Simul Comput. 2008;37(7):1263-1269.
30. Smithson M, Verkuilen J. A better lemon squeezer? Maximum-likelihood regression with beta-distributed dependent variables. Psychol Methods. 2006;11(1):54-71.
31. Verkuilen J, Smithson M. Mixed and mixture regression models for continuous bounded responses using the beta distribution. J Educ Behav Stat. 2012;37(1):82-113.
32. Jack CR, Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC, Cascino GD. Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology. 1989;172(2):549-554.
33. Siddiqui O, Hung HM, O'Neill R. MMRM vs LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat. 2009;19(2):227-246.
34. Kleinbaum DG, Klein M. Survival Analysis. A Self-Learning Text. 2nd ed. New York, NY: Springer; 2005.
35. Friberg LE, de Greef R, Kerbusch T, Karlsson MO. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther. 2009;86(1): 84-91.
36. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201-209.
37. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003;31(5):510-518.
38. Janssen Research and Development, LLC. A study to evaluate the effects of JNJ-54861911 on amyloid beta processing in cerebrospinal fluid and plasma in patients with prodromal Alzheimer's disease. Available from: http://clinicaltrials.gov/ct2/show/NCT01978548?term=CSF Aβ1-42&rank=2. NLM identifier: NCT01978548. Accessed December 1, 2013.
39. Merck Sharp and Dohme Corp. Efficacy and safety trial of MK-8931 in participants with prodromal Alzheimer's disease (MK-8931-019) (APECS). Available from: http://clinicaltrials.gov/ct2/show/NCT01953601?term=abetaMK&rank=3. NLM identifier: NCT01953601. Accessed December 1, 2013.
40. Bristol-Myers Squibb. A multicenter, double blind, placebo-controlled, safety and tolerability study of BMS-708163 in patients with prodromal Alzheimer's disease. Available from: http://clinicaltrials.gov/ct2/show/NCT00890890?term=BMS-708163&rank=8. NLM identifier: NCT00890890. Accessed December 1, 2013.
41. Tondelli M, Wilcock GK, Nichelli P, De Jager CA, Jenkinson M, Zamboni G. Structural MRI changes detectable up to ten years before clinical Alzheimer's disease. Neurobiol Aging. 2012;33(4):825. e25-e825. e36.
42. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216.
43. Landau SM, Harvey D, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75(3):230-238.